Friday March 15, 2013 0 comments
BOULDER - N30 Pharmaceuticals Inc. announced it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis.
The study is a multi-center, double-blind, randomized placebo-controlled evaluation of ascending doses of the drug in patients with two copies of the F508del-CFTR mutation, the most common and serious form of CF, N30 said.
The clinical study is being conducted in collaboration with the Cystic Fibrosis Foundation's Therapeutics Development Network (TDN).
The first patient was dosed this week at National Jewish Health in Denver. The primary objective of the study is to evaluate the safety of repeat doses of N6022. Secondary objectives include evaluating its serum levels, lung function and other markers of disease activity, N30 said.
"We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation," said Charles Scoggin, N30's president and CEO.
"With this first trial, we look forward to paving the way to a new class of therapy for cystic fibrosis."
For more information, visit www.n30pharma.com.